体内
人脑
萎缩
病理
转基因小鼠
共核细胞病
化学
正电子发射断层摄影术
体外
中枢神经系统
小脑
蛋白质聚集
临床前影像学
医学
代谢物
纤维
神经科学
离体脑
脑组织
白质
重组DNA
病态的
Pet成像
淀粉样蛋白(真菌学)
切片制备
生物物理学
药物开发
神经影像学
分子成像
转基因
路易氏体型失智症
血浆蛋白结合
生物
作者
Ran Sing Saw,Sabrina Haas,Felix Schmidt,Sergey Ryazanov,Andrei Leonov,Daniel Bleher,Ann-Kathrin Grotegerd,Laura Kuebler,Benjamin Röeben,Fabian P. Schmidt,Matthias Reimold,Federica Bonanno,Viktoria Ruf,Bernadette Dahl,Christine M. Sandiego,Kelly E. Henry,Ioannis Papadopoulos,Martin Schaller,Philipp J. Kahle,Johannes Levin
标识
DOI:10.1126/scitranslmed.aec0813
摘要
Synucleinopathies are neurodegenerative diseases characterized by the presence of brain inclusions containing the pathologically aggregated protein α-synuclein. The development of a positron emission tomography tracer to detect aggregates of misfolded α-synuclein could revolutionize early diagnosis, disease monitoring, and the evaluation of therapeutic efficacy. Here, we present the development, preclinical validation, and first-in-human evaluation of [ 11 C]MODAG-005. In vitro binding experiments demonstrated subnanomolar binding affinity to recombinant α-synuclein fibrils and to α-synuclein inclusions in human brain tissue. Specific binding in multiple system atrophy (MSA) brain tissue was detected using autoradiography and microautoradiography and was validated through immunostaining. In vivo, [ 11 C]MODAG-005 showed good brain penetration, rapid clearance from brain tissue, and low metabolite formation in rodents and nonhuman primates. In addition, a pronounced binding and a good signal-to-noise ratio were achieved in an α-synuclein fibril–injected rat model and in an α-synuclein (A30P) transgenic mouse model in correlation to the pathological load. To validate the potential of [ 11 C]MODAG-005 for therapeutic development, we showed target engagement of the drug candidate anle138b in the brain tissues from α-synuclein (A30P) mice and patients with multiple system atrophy as well as in vivo in α-synuclein fibril–injected rats. Last, first-in-human imaging demonstrated [ 11 C]MODAG-005 binding in brain regions affected by α-synuclein pathology in patients with clinically established MSA cerebellar type, MSA cerebellar and parkinsonian type, and Parkinson’s disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI